Jonathan W Riess

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
    Jonathan W Riess
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
    Cancer Invest 30:231-5. 2012
  2. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    From the aDepartment of Medicine, Division of Oncology, and bDepartment of Neurology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California
    J Natl Compr Canc Netw 11:389-94. 2013
  3. doi request reprint ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
    Millie Das
    Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
    Lung Cancer 77:421-6. 2012
  4. ncbi request reprint Metastatic non-small cell lung cancer management: novel targets and recent clinical advances
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Adv Hematol Oncol 10:226-34. 2012

Collaborators

Detail Information

Publications4

  1. doi request reprint Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
    Jonathan W Riess
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
    Cancer Invest 30:231-5. 2012
    ..268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients...
  2. ncbi request reprint A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib
    Jonathan W Riess
    From the aDepartment of Medicine, Division of Oncology, and bDepartment of Neurology, Division of Neuro Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California
    J Natl Compr Canc Netw 11:389-94. 2013
    ....
  3. doi request reprint ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
    Millie Das
    Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, USA
    Lung Cancer 77:421-6. 2012
    ....
  4. ncbi request reprint Metastatic non-small cell lung cancer management: novel targets and recent clinical advances
    Jonathan W Riess
    Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Adv Hematol Oncol 10:226-34. 2012
    ..This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment...